Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 1 August 2019, 10:41 HKT/SGT
Share:
    

Source: Eisai
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package

TOKYO, Aug 1, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019.


SAHNE brand marks its 65th anniversary this year. Since the initial launch, SAHNE CREAM has been close to the lifestyle of women who have changed with the times. Eisai is aiming for a brand used by generations around 30's, and will respond to the today's woman needs of easy and simple care at anytime and anywhere such as at home, office, and outside by this refresh of SAHNE CREAM.

The brand name SAHNE is originated from the German word for "cream", and is named under the image of fluffy and smooth of whipped cream. SAHNE CREAM, which has been particular about skin absorbing cream, is quickly absorbing and not sticky, and can be quickly applied on hands, fingers, and whole body care such as neck, decollete, elbows, knees, and heels during housework, childcare, and work as daily care of bare skin.

Compared to the existing products, new SAHNE CREAM has refreshed with mild scent, and the design has changed based on English logo SAHNE and red, which it blends in with the everyday life of mature women while maintaining the moisture and smooth comfort ability.

Eisai is striving to deliver a rich daily life to a wider range of customers through SAHNE CREAM, and to contribute for further improvement of benefits with products and services that meet diverse needs with staying close to customers' lives.


Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: